Please complete this form relating to your transactions for Depomed, Inc.(Nasdaq: DEPO) securities between February 26, 2015 and August 7, 2017, inclusive (the "Class Period").
You may also contact James Maro, Esq. at (484) 270-1453; or you may submit your information via email at firstname.lastname@example.org, or you may click here to print a PDF of this form.
On August 18, 2017, the initial complaint in this securities class action was filed against Depomed, Inc. (“Depomed” or the “Company”), and certain of Depomed’s directors, officers and underwriters, asserting violations of sections 10(b) and 20(a) of the Securities Exchange Act.
The complaint alleges that throughout the class period, defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Depomed engaged in questionable practices in connection with the sales and marketing of the Company’s opioid products; (ii) the foregoing conduct, when it became known, would likely subject the Company to heightened legal and regulatory scrutiny; and (iii) as a result, Depomed’s public statements were materially false and misleading at all relevant times.
Current Status of Case:
On March 11, 2020, the Court granted defendants’ Motion to Dismiss. On April 9, 2020, Plaintiffs filed an appeal with the United States Court of Appeals for the Ninth Circuit. This action is still ongoing.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453; or via e-mail at email@example.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.